Phase 3 explorer7 longer-term results in 133 male patients aged >=12 with haemophilia A or B with inhibitors: median annualised bleeding rate on concizumab prophylaxis was 0.8 at the 56-week cutoff, consistent with 32-week results; no new safety concerns.
RCTn = 133
Mahlangu et al. Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study